BioCentury | Mar 12, 2001
Clinical News

recombinant human CC10 (rhCC10) uteroglobin: Began Phase I trial

...A2 Indication: Prevent lung disease in premature infants End point: Safety, tolerability and pharmacokinetics Status: Claragen...
BioCentury | Jun 9, 1997
Company News

Claragen, National Institutes of Health deal

...fibronectin-binding protein. Uteroglobin treatment is intended to prevent fibrosis associated with BPD and kidney disease. ClaraGen Inc....
Items per page:
1 - 2 of 2
BioCentury | Mar 12, 2001
Clinical News

recombinant human CC10 (rhCC10) uteroglobin: Began Phase I trial

...A2 Indication: Prevent lung disease in premature infants End point: Safety, tolerability and pharmacokinetics Status: Claragen...
BioCentury | Jun 9, 1997
Company News

Claragen, National Institutes of Health deal

...fibronectin-binding protein. Uteroglobin treatment is intended to prevent fibrosis associated with BPD and kidney disease. ClaraGen Inc....
Items per page:
1 - 2 of 2